Revive Therapeutics Expands into Phase III Clinical Trials

August 26, 2020

Revive Therapeutics Expands into Phase III Clinical Trials

Revive Therapeutics will expand their candidate, Bucillamine, in patients with mild-moderate COVID-19 in phase III trials taking place in the Asia-Pacific Countries (“APAC”) and Canada. Revive expects to open the Phase 3 clinical trial for patient enrollment and dosing in September 2020. Yourway has a depot in Mississauga, Ontario in Canada, as well as in Beijing, China, Tokyo, Japan, Singapore, and Adelaide, Australia.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

SCOPE Supply Chain & Logistics Leadership Summit

February 2-5, 2026
Orlando, Florida

Schedule a Meeting

Global Clinical Supplies Group Asia Pacific Conference

March 10-12, 2026
Conrad Seoul Hotel, South Korea

Schedule a Meeting

Media

Articles

When is it time to switch to a biopharma-specialized courier?

Open chat

Hello! How can I help you?